News

Stacking the Odds in Alzheimer's Disease Drug Development
Stacking the Odds in Alzheimer's Disease Drug Development
September 20, 2016

We have been developing several drugs that modulate the phosphorylation of the aggregating protein tau in Alzheimer’s disease by inhibiting the protein casein kinase 1 delta. We have tested them in a model of human tauopathy (aggregating tau diseases) and analyzed brain tissue with SysQuant® to determine the drug’s mechanism of action.

Proteome Sciences Interim Results
Proteome Sciences Interim Results
September 15, 2016
“We are pleased to report that performance during the first six months of 2016 has been in line with expectations, and it is encouraging that revenues remain well ahead of the equivalent period in 2015
Trading Update and Notice of Results
Trading Update and Notice of Results
July 28, 2016

Revenues in the first half are significantly ahead of the equivalent period in 2015 driven principally by strong sales of our TMT® reagents.

AGM Statement and Result of AGM
AGM Statement and Result of AGM
June 24, 2016
At the AGM held earlier today it was announced that revenues from the core biomarker services activities remained buoyant in the first half with a strong order book, including repeat business, and a developing pipeline. TMT revenue growth has continued into 2016 and TMT was highly visible at the recent meeting of the American Society for Mass Spectrometry. The growing recognition of tau as a therapeutic target in Alzheimer’s disease should increase interest in new treatments which could…
Publication of Annual Reports and Accounts 2015
Publication of Annual Reports and Accounts 2015
June 1, 2016
The Company announces that its Annual Report and Accounts for the year ended 31 December 2015, together with a notice of the Annual General Meeting and accompanying form of proxy, are available to view on the Company’s website at www.proteomics.com, and will be posted to shareholders imminently.
CEO Appointment
CEO Appointment
June 1, 2016

We are pleased to announce the appointment of Jeremy Haigh as a director and CEO of the Company on 1st June 2016 as indicated in the press release to shareholders dated 18th May 2016. He is a strong advocate of Precision Medicine and will bring numerous industry contacts and considerable commercial experience to the role.

Adding Precision to Medicine - Annual Report and Accounts 2015
Adding Precision to Medicine - Annual Report and Accounts 2015
May 31, 2016
We have benefitted from a good performance in all aspects of the business in 2015, in particular biomarker services where there has been strong customer adoption of SysQuant® and TMTcalibrator™ with the focus on Precision Medicine. Considerable scientific progress has been made over the period, particularly in Alzheimer’s disease (Ad) across a number of different areas and these have formed the backcloth to the prominent releases and presentations that we have made…
CEO Appointment
CEO Appointment
May 18, 2016

Against the buoyant background and trajectory of the PS Biomarker Services business it is now appropriate to expand the executive team with a senior figure strongly connected to the pharmaceutical industry and to split the role of Executive Chairman.

Preliminary Results for Year Ended December 31st, 2015
Preliminary Results for Year Ended December 31st, 2015
May 18, 2016

The current year started well with a strong order book, increasing amounts of repeat business and a growing pipeline in biomarker services. With the level of SysQuant® /TMTcalibrator™ production doubled the increased capacity is being fully utilised at a time when the volume of customer enquiries is rising on a monthly basis and we are looking to further expand the sales team. Current indications point to a strong performance in 2016. 

Block Admission Report
Block Admission Report
April 5, 2016